TNF neutralization in MS

  title={TNF neutralization in MS},
  author={Arnason Bgw. and G Jacobs and Matthew Hanlon and Brian Clay and Noronha Abc. and Anthony Auty and Bradley E. Davis and Avindra Nath and J-P. Bouchard and C Belanger and France Gosselin and Manon Thibault and Pierre Duquette and Pierre Bourgoin and R. Dubois and Marc P. Girard and George Cornell Ebers and Rice Gpa. and Margaret K. Vandervoort and Gordon S. Francis and Lauren Duncan and Yves Lapierre and Mark Steven Freedman and Suzanne N. Christie and Hyman H. Rabinovitch and David G. Patry and William F. Murphy and S. Peters and S{\'e}amus McGuiness and Thomas J. Murray and Virender Bhan and Charles E. Maxner and R. A. Van Dorpe and Jo{\"e}l J. -F. Oger and James Nelson and W. Morrison and N Bogle and Sarah Beall and G. Vorobeychick and Anita Hiltbrunner and Jason Bock and Werner Lesslauer and Li Dkb. and Donald W. Paty and Guojun Zhao and Grp Lmss. and Grp Ubcmsmria.},
  pages={457 - 457}
Objective: A double-blind, placebo-controlled phase II study was conducted in 168 patients, most with relapsing-remitting MS, to evaluate whether lenercept would reduce new lesions on MRI. Background: Tumor necrosis factor (TNF) has been implicated in MS pathogenesis, has been identified in active MS lesions, is toxic to oligodendrocytes in vitro, and worsens the severity of experimental allergic encephalomyelitis (EAE) in animals. Lenercept, a recombinant TNF receptor p55 immunoglobulin fusion… 

Figures and Tables from this paper

Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis
It was found that only patients who received antibodies to IFN-g showed statistically significant improvement compared to the placebo group-a significant increase in the number of patients without confirmed disability progression, which could be a new approach to treating secondary progressive MS.
Clinical features and genetic risk of demyelination following anti-TNF treatment.
Patients who experienced demyelination events following anti-TNF were more likely female, less frequently treated with an immunomodulator, and had a similar genetic risk to anti- TNF exposed controls who did not.
Pirfenidone for chronic progressive multiple sclerosis
Pirfenidone appears to offer protection against the usual slow progression of the disease, and most patients experienced a distinct decrease in their neurological disability, indicating that an extensive multi-center double blind and placebo controlled trial is warranted.
Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
  • T. Nomura, Y. Abe, Y. Tsutsumi
  • Biology
    Journal of controlled release : official journal of the Controlled Release Society
  • 2011
A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Infliximab was an effective short-term immunosuppressive agent in most of the patients, with 18 of 23 meeting criteria for clinical success at week 10, and the rate of serious toxic effects was unexpectedly high.
Demyelinating Neurological Adverse Events following the Use of Anti-TNF-α Agents: A Double-Edged Sword
Three cases of demyelination after the use of anti-TNF-α agents are presented and it is concluded that on suspicion of any neurological side effects, early discontinuation of the TNF- α blockers and requesting urgent MRI scan to confirm the diagnosis is of utmost importance.
The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
  • P. Sfikakis
  • Medicine, Biology
    Current directions in autoimmunity
  • 2010
It is hoped that more efficacious drugs that will ideally target the deleterious proinflammatory properties of TNF without compromising its protective role in host defense and (auto)immunity will be available in the near future.
Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review
The results of the present review suggest that demyelinating diseases associated with TNFi are extremely rare, however, with clinical vigilance and individualized treatment regimen, TNFi may be safe for use in other patients.


Childhood multiple sclerosis: Clinical features and demonstration of changes in T cell subsets with disease activity
The finding that young children with active MS have a pattern of T cell abnormalities identical to that of adult MS patients suggests that the same pathophysiological process which causes MS in adults occurs in young children as well.
Immunological aspects of demyelinating diseases.
Recent research in MS has been focused on the characterization of cellular immune responses against myelin components and the results of these studies are reviewed and the potential implications for the pathogenesis and future therapy of MS are examined.
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
To provide international consensus guidelines for the use of MRI in MS clinical trials, a task force of the US National MS Society was convened and the recommendations of the task force are presented in this review.
A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis.
Clinical improvement was accompanied by a marked decrease in abnormal pathological findings, including demyelination, and anti-alpha 4 is an effective treatment of EAE and may be similarly useful in the treatment of autoimmune diseases such as multiple sclerosis.
Multiple sclerosis in childhood: long term katamnestic investigations.
In addition to the "classical" symptoms known in adult, multiple sclerosis, papilloedema and acute increased intracranial pressure were observed in nine children, and dehydrating treatment was life saving in these cases.
A monoclonal antibody to α4‐integrin reverses the MR‐detectable signs of experimental allergic encephalomyelitis in the Guinea pig
Experimental allergic encephalomyelitis is a T cell‐mediated autoimmune disease of the CNS characterized by blood‐brain barrier breakdown, and is used as an animal model of multiple sclerosis (MS).
Multiple sclerosis in childhood
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.
The outcome of multiple sclerosis, assessed according to the Kurtzke Disability Status Scale, was reviewed in 1,099 consecutive patients followed in London, Canada, between 1972 and 1984 and the rate at which disability develops after the onset of a progressive phase of MS is presented.
Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.
  • J. G. Phadke
  • Medicine, Psychology
    Brain : a journal of neurology
  • 1990
The prognosis and course of multiple sclerosis (MS) and the factors that affect them were assessed in a group of 1055 patients, representing an unselected (epidemiological) sample observed in the